Filligent Limited was founded by Melissa Mowbray-d’Arbela and Neal Stewart in 2001 with a combined vision to build a company that would lead the world in innovative, effective, ethical and timely ways to solve today’s most pressing health challenges.
Within its first decade, Filligent became a thought leader in disease intervention and prevention and transformed the industry landscape with the introduction of its groundbreaking range of antimicrobial and reduced toxicity products. In recognition of this, Goldman Sachs became an investor in 2006.
Filligent’s laboratories and headquarters are in Hong Kong, with manufacturing facilities in the US and China.
The company is committed to delivering affordable, pragmatic, and advanced protective health solutions to every strata of society.